Jason Duncan - 22 Apr 2022 Form 4 Insider Report for ALBIREO PHARMA, INC.

Role
Chief Legal Officer and GC
Signature
/s/ Jason Duncan
Issuer symbol
N/A
Transactions as of
22 Apr 2022
Net transactions value
-$21,758
Form type
4
Filing time
25 Apr 2022, 16:38:59 UTC
Previous filing
25 Jan 2022
Next filing
25 Jul 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALBO Common Stock Sale $7,937 -240 -1.4% $33.07 16,423 22 Apr 2022 Direct F1, F2
transaction ALBO Common Stock Sale $3,391 -103 -0.63% $32.93 16,320 22 Apr 2022 Direct F3, F4
transaction ALBO Common Stock Sale $7,390 -221 -1.4% $33.44 16,099 25 Apr 2022 Direct F1, F5
transaction ALBO Common Stock Sale $3,039 -91 -0.57% $33.40 16,008 25 Apr 2022 Direct F3, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2021.
F2 Represents 591 shares of common stock and 15,832 restricted stock units.
F3 Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
F4 Represents 488 shares of common stock and 15,832 restricted stock units.
F5 Represents 579 shares of common stock and 15,520 restricted stock units.
F6 Represents 488 shares of common stock and 15,520 restricted stock units.